NAICS Code 325412-05 - Medicines-Patent (Manufacturing)

Marketing Level - NAICS 8-Digit

Business Lists and Databases Available for Marketing and Research

Total Verified Companies: 9
Contact Emails: 288
Company Websites: 9
Phone Numbers: 8
Business Addresses: 9
Companies with Email: 7
Get Business List
NAICS CODE 325412-05
Reach new customers, connect with decision makers, and grow your business.
Pricing from $0.05 to $0.25 per lead
Ideal for: Direct Mailing Email Campaigns Calling Market Research ‐ Free Sample & Report, Custom Lists, and Expert Support — All Included
Looking for more companies? See NAICS 325412 - Pharmaceutical Preparation Manufacturing - 1,726 companies, 213,574 emails.

NAICS Code 325412-05 Description (8-Digit)

Medicines-Patent (Manufacturing) is a subdivision of the Pharmaceutical Preparation Manufacturing industry that involves the production of patented medicines. These are medications that have been granted a patent by the government, giving the manufacturer exclusive rights to produce and sell the drug for a certain period of time. The manufacturing process for these medicines involves a range of complex procedures to ensure the drug is produced to the highest quality standards and meets all regulatory requirements.

Parent Code - Official US Census

Official 6‑digit NAICS codes serve as the parent classification used for government registrations and documentation. The marketing-level 8‑digit codes act as child extensions of these official classifications, providing refined segmentation for more precise targeting and detailed niche insights. Related industries are listed under the parent code, offering a broader context of the industry environment. For further details on the official classification for this industry, please visit the U.S. Census Bureau NAICS Code 325412 page

Tools

Tools commonly used in the Medicines-Patent (Manufacturing) industry for day-to-day tasks and operations.

  • High-performance liquid chromatography (HPLC)
  • Gas chromatography (GC)
  • Mass spectrometry (MS)
  • Nuclear magnetic resonance (NMR) spectroscopy
  • Lyophilizers
  • Microfluidizers
  • Homogenizers
  • Autoclaves
  • Fermenters
  • Centrifuges
  • Freeze dryers
  • Tablet presses
  • Capsule fillers
  • Coating machines
  • Blister packaging machines
  • Labeling machines
  • Sterilization equipment
  • Cleanrooms
  • HVAC systems

Industry Examples of Medicines-Patent (Manufacturing)

Common products and services typical of NAICS Code 325412-05, illustrating the main business activities and contributions to the market.

  • Anti-inflammatory drugs
  • Antidepressants
  • Antipsychotics
  • Blood thinners
  • Chemotherapy drugs
  • Diabetes medications
  • Hormone replacement therapy drugs
  • Immunosuppressants
  • Painkillers
  • Vaccines

History

A concise historical narrative of NAICS Code 325412-05 covering global milestones and recent developments within the United States.

  • The "Medicines-Patent (Manufacturing)" industry has a long and rich history worldwide. One of the earliest examples of patent medicine was the "Elixir of Vitriol," which was a mixture of sulfuric acid, alcohol, and herbs. In the United States, the industry began to take shape in the late 19th century, with the rise of companies like Pfizer and Eli Lilly. These companies were responsible for many of the early breakthroughs in the industry, including the development of penicillin and other antibiotics. In recent years, the industry has continued to evolve, with the rise of biotech companies and the increasing importance of personalized medicine. In the United States, the "Medicines-Patent (Manufacturing)" industry has undergone significant changes in recent years. One of the most notable developments has been the rise of generic drugs, which now account for a significant portion of the market. Another important trend has been the increasing focus on research and development, with many companies investing heavily in new drug discovery. Additionally, the industry has faced significant regulatory challenges, including increased scrutiny from the FDA and other government agencies. Despite these challenges, the industry remains a vital part of the US economy, with many companies continuing to innovate and develop new treatments for a wide range of diseases and conditions.